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ABSTRACT
Lipopolysaccharide (LPS) is currently considered one of the major players in 
non-alcoholic fatty liver disease (NAFLD) pathogenesis and progression. Here, we 
aim to investigate the possible role of LPS-induced TNF-a factor (LITAF) in inducing a 
pro-inflammatory and pro-fibrogenic phenotype of non-alcoholic steatohepatitis (NASH).
We found that children with NAFLD displayed, in different liver-resident cells, 
an increased expression of LITAF which correlated with histological traits of hepatic 
inflammation and fibrosis. Total and nuclear LITAF expression increased in mouse 
and human hepatic stellate cells (HSCs). Moreover, LPS induced LITAF-dependent 
transcription of IL-1β , IL-6 and TNF-a in the clonal myofibroblastic HSC LX-2 cell line, 
and this effect was hampered by LITAF silencing. We showed, for the first time in 
HSCs, that LITAF recruitment to these cytokine promoters is LPS dependent. However, 
preventing LITAF nuclear translocation by p38MAPK inhibitor, the expression of 
IL-6 and TNF-a was significantly reduced with the aid of p65NF-ĸB, while IL-1β 
transcription exclusively required LITAF expression/activity. Finally, IL-1β levels in 
plasma mirrored those in the liver and correlated with LPS levels and LITAF-positive 
HSCs in children with NASH.
In conclusion, a more severe histological profile in paediatric NAFLD is associated 
with LITAF over-expression in HSCs, which in turn correlates with hepatic and 
circulating IL-1β levels outlining a panel of potential biomarkers of NASH-related 
liver damage. The in vitro study highlights the role of LITAF as a key regulator of the 
LPS-induced pro-inflammatory pattern in HSCs and suggests p38MAPK inhibitors as 
a possible therapeutic approach against hepatic inflammation in NASH.
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BACKGROUND
Over the past few years, the study of the gut-liver 
axis involvement in the pathogenesis of chronic liver 
diseases has become of central importance. Notably, 
it has been reported that the Toll-like receptor (TLR)-4 
signalling cascade initiated by gut endotoxins, including 
lipopolysaccharide (LPS), is involved in the development 
and progression of chronic liver injury [1]. Importantly, 
several lines of evidence have described the involvement 
of the LPS/TLR-4 pathway in non-alcoholic fatty liver 
disease (NAFLD) pathogenesis and in its progression 
to the more severe form of non-alcoholic steatohepatitis 
(NASH) [1, 2]. A close relationship between augmented 
circulating LPS levels, fibrosis and NASH severity has 
been reported both in human subjects and in animal 
models. In particular, clinical studies have shown 
increased LPS plasma levels in the systemic and portal 
circulation of patients with cirrhosis [3, 4]. Accordingly, 
obese paediatric patients with NAFLD/NASH display 
elevated serum LPS levels, a finding which correlates with 
the severity of disease [5]. Moreover, in NAFLD/NASH 
animal models the disruption of intestinal integrity leads to 
increased LPS translocation, TLR-4 signalling activation, 
hepatic inflammation and fibrogenesis [6]. Coherently, the 
blockage of LPS/TLR-4 signalling, via genetic ablation 
of TLR-4 or via alteration of intestinal microbiota either 
by antibiotics or by probiotics protects patients from 
diet-induced NAFLD and fibrosis [7, 8]. Furthermore, 
an important role for gut microbiota imbalance has been 
suggested in NASH patients, who exhibited a sterile 
pro-inflammatory pattern and an augmented hepatic 
TLR-4 expression [9, 10]. Studies also have shown that 
TLR- 4/dysbiosis plays a critical role in the progression of 
NAFLD [11, 12].
The LPS-induced tumour necrosis factor (TNF)-α 
factor (LITAF), alternatively known as small integral 
membrane protein of the lysosome/late endosome 
(SIMPLE) and as p53 inducible gene-7 (PIG-7) protein, 
has been initially identified as a p53-inducible target in 
DLD-1 colon cancer cell lines [13]. Together with nuclear 
factor kappa-B (NF-ĸB), LITAF has been identified as 
a novel cis-acting regulatory protein crucial for human 
LPS-dependent transcription of TNF-α gene in human 
monocytic THP-1 leukaemia cells [14]. The LITAF gene 
maps to chromosome 16p12–16p13.3 in humans and 
high levels of its mRNA are found mainly in placenta, 
peripheral blood leukocytes, lymph nodes and spleen [14]. 
The LITAF protein is primarily expressed in monocytes/
macrophages and spleen, but also in bone marrow, brain, 
heart, lung and liver [15]. Importantly, whole-body 
LITAF deficiency has a dramatic effect on systemic and 
chronic local inflammatory responses [15]. LITAF is 
currently considered one of the most important players 
in the activation of pro-inflammatory molecules under 
LPS stimulation in macrophages [16, 17]. Specifically, 
Tang et al. demonstrated, through footprinting analysis, 
that the human LITAF binds a CTCCC (−515 to −511) 
responsive element within the TNF-α promoter [16]. The 
authors further identified a LITAF region (amino acids 
165–180) that mediates the binding between LITAF and 
the TNF-α promoter, called the peptide B [16]. They also 
demonstrated that macrophage-specific LITAF-deficient 
mice (macLITAF−/−) exhibited a resistance to LPS-
induced lethality and a decreased expression of various 
cytokines, including TNF-α, interleukin (IL)-6, soluble 
TNF-α receptor II and chemokine CXCL16 [17].
LITAF has been indicated as an important player 
connecting inflammation, obesity and associated disorders, 
such as NAFLD. In particular, a positive correlation 
between LITAF expression in human peripheral 
monocytes and obesity, insulin resistance and plasmatic 
pro-inflammatory cytokines levels has been reported 
[18]. We recently demonstrated that LITAF mRNA and 
protein expression is up-regulated in rat models with 
diet-induced NAFLD. In light of this, we proposed that 
this molecule could be a novel factor for mediating the 
LPS/TLR-4 axis during development and progression 
of the disease [19]. Despite plentiful evidence regarding 
LITAF regulation in macrophage populations, to date 
no studies have clarified LITAF involvement in the pro-
inflammatory and pro-fibrogenic pathways related to 
liver disorders. Since increased endotoxemia and TLR-
4 signalling play a major role in the activation of pro-
inflammatory and pro-fibrogenic phenotype in hepatic 
stellate cells (HSCs), the potential role of LITAF in these 
mechanisms should be investigated [7].
Here, we show that LITAF expression and activity 
increase under LPS exposure. We identify LITAF as a key 
regulator of the LPS-induced pro-inflammatory pattern in 
HSCs. Accordingly, the increased expression of LITAF in 
whole liver and in HSCs is strongly associated with a more 
severe histological profile of inflammation and fibrosis in 
children with NAFLD. Moreover, our data suggests the 
use of p38MAPK inhibitors as a promising therapeutic 
approach to treating hepatic inflammation in NASH.
RESULTS
Children with NAFLD exhibit hepatic over-
expression of LITAF as a tracer of liver 
damage progression
We previously reported an up-regulation of LITAF 
transcript consistent with the increased expression of 
hepatic LITAF protein levels in high-fat/high-fructose 
diet-induced NAFLD in rats [19]. In the present study, we 
analysed expression levels of LITAF mRNA and protein 
in children with biopsy-proven NAFLD. The diagnosis of 
NAFLD was established following a standard clinical and 
histological workup as previously described [20]. Sample 
collection and use was performed after obtaining approval 
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of the Ethical Committee of the Bambino Gesù Children’s 
Hospital and written consent by parents of the children.
The analysis of the liver protein expression showed 
a significant increase of LITAF levels corresponding 
to disease severity progression measured in terms of 
NAFLD activity score (NAS), and the presence of 
NASH (Fig. 1A, upper panels and 1B). Moreover, LITAF 
protein expression levels increased consistently with the 
severity of fibrosis (Fig. 1A, lower panels and 1D) and 
of inflammation (Fig. 1C) assessed by Kleiner scores 
[21]. Quantitative Real Time-PCR (qRT-PCR), revealed 
not significant changes in mean LITAF mRNA levels 
with respect to the presence of NASH and grading of 
inflammation and fibrosis (Fig. S1A).
Whatever aetiology, liver fibrosis is a wound healing 
response to liver injury, involving proliferation and 
activation of HSCs towards a myofibroblast phenotype 
that accumulates stress fibers, mainly characterized by 
α-smooth muscle actin (α-SMA) over-expression [22, 23]. 
As shown Fig. 1E, the increased severity of fibrosis and 
inflammation, expressed in terms of both histological 
scores and α-SMA or CD68 positivity for macrophages, 
correlated with LITAF up-regulation in children with 
NAFLD. Interestingly, the number of CD163/LITAF 
positive M2 macrophages increased with severity of 
inflammation (Fig. S1B).
Importantly, the number of LITAF/α-SMA positive 
HSCs was higher in NAFLD children with F = 1 than in 
those with F = 0, and continued to increase with fibrosis 
progression (Fig. 1F). Moreover, α-SMA positive HSCs 
and cytokeratin 8/18 (CK8/18) positive hepatocytes 
exhibited an increased expression of LITAF protein in 
NAFLD livers compared to those from 8 healthy children 
(Fig. S1C).
Activated primary mouse HSCs display  
serum-dependent increase of LITAF expression/
activity and inflammation
Primary cultured mouse HSCs were activated on 
plastic, serum starved for 24 h, and then treated with either 
1% (HSC-1) or 10% FBS (HSC-10) at different timepoints 
Figure 1: Hepatic LITAF expression increases in NAFLD children correlating with histological traits of hepatic 
inflammation and fibrosis. A. Immunoblot analysis of total LITAF protein expression in liver from NAFLD children according to 
NAS and fibrosis (n = 25). The immunoblot is representative of 3 different Western Blottings. Lanes were run on the same gel but were 
non-contiguous. B–D. Quantitative densitometric analysis of LITAF protein expression in patients (B) with NASH vs. NotNASH, (C) 
with I = 0 vs. I = 1 vs. I = 2 and (D) F = 0 vs. F = 1, vs. F = 2 vs. F = 3. Histogram represents the mean values ± standard deviation (SD). 
E. Representative confocal imaging of α-SMA/LITAF (green/red) and CD68/LITAF (green/red) respect to fibrosis (0–3) and inflammation 
(0–2) grading in liver tissues from NAFLD children (n = 25). The nuclei are in blue (scale bar: 50 μm for fibrosis; scale bar: 100 μm for 
inflammation). F. Representative confocal laser microscopy of LITAF (grey) and α-SMA (green) in liver tissues from NAFLD children. The 
two labels are merged with nuclei. Nuclei were counterstained with DAPI (blue) (scale bar: 50 μm). The histogram represents the mean ± 
SD of LITAF/α-SMA positive HSCs in samples with F = 0 vs. F = 1 vs. F = 2 vs. F = 3 (n = 25). Differences across groups were analysed 
by Student’s two-tailed or ANOVA as appropriate. *p < 0.05, **p < 0.01, ***p < 0.001.
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(2, 3 and 6 h). We first explored the expression of LITAF 
mRNA and protein in HSC-1 and HSC-10 at 2 h. We found 
a significant increase of α-SMA mRNA but no change 
of LITAF mRNA levels in HSC-10 compared to HSC-1 
(Fig. 2A). However, Western Blotting analysis showed 
that LITAF protein, almost absent in HSC-1, is strongly 
up-regulated in HSC-10 at 3 h (Fig. 2B). As Tang et al [17] 
demonstrated that the transcriptional activity of LITAF 
could depend on its nuclear translocation in macrophages, 
we then investigated LITAF and α-SMA intra-cellular 
distribution. Confocal laser microscopy showed that at 
2 h LITAF and α-SMA expression were higher in HSC-10 
than HSC-1 (Fig. 2C). Furthermore, quantitative imaging 
analysis performed by a novel dedicated bioinformatic 
pipeline (Fig. S2A) revealed that LITAF nuclear amount 
was predominant in HSC-10 (Fig. 2D).
Once activated, HSCs migrate and accumulate in the 
damaged sites secreting a large quantity of extracellular 
matrix proteins and fibrillar collagens [22, 24–27]. The 
autocrine and paracrine perpetuation of HSC activation 
is sustained by increased production and/or activity of a 
wide array of cytokines [25]. Accordingly, by the usage 
Figure 2: LITAF expression/activity and inflammatory response is upsized by serum in activated primary mouse 
HSCs. A–F. Primary mouse activated HSCs were serum starved for 24 h and then treated with either 1% (HSC-1) or 10% FBS (HSC-10) 
at different timepoints. A: QRT-PCR analyses of α-SMA and LITAF mRNA expression at 2 h (n = 3). B: Immunoblot analysis of total LITAF 
at 3 h (data presented is representative of three independent experiments). C: Representative confocal imaging of α-SMA (blue), LITAF 
(red) and nuclei (stained with DRAQ5, white) at 2 h (scale bar: 20 μm). D: Quantitative imaging analysis of LITAF nuclear translocation 
(n cells > 50). Mann-Whitney U test. E: Semi-quantitative protein expressions of IL-1β, IL-6 and TNF-α in total cell lysate of HSC-1 and 
HSC-10 by using a Cytokine Antibody Array (n = 2 in duplicate) at 3 h. F: QRT-PCR analyses of COL1, COL6 and TGF-β at 2 h (n = 3). 
Histograms represent the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 vs. HSC-1, Student’s t test.
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of a sensitive antibody (Ab) array approach containing 
Abs against 40 specific cytokines (Fig. S2B), we found 
that the expression of several pro-inflammatory cytokines, 
including IL-1β, IL-6 and TNF-α, was significantly 
up-regulated in the HSC-10 with respect to HSC-1 
phenotype after 3 h from FBS supplementation (Fig. 2E 
and Fig. S2C and S2D). It is well known that HSCs can 
change to a myofibroblast-like activated phenotype, 
characterized by the increased α-SMA expression and by 
production and secretion of a large amounts of collagens, 
including type I (COL1) and type VI (COL6) collagens, 
and pro-fibrogenic cytokines, such as transforming 
growth factor (TGF)-β [28]. However, we found that 
the prolongation of the activation state by 10% FBS had 
no further activating effects on HSCs. In fact, qRT-PCR 
confirmed that COL1 mRNA significantly decreased, 
TGF-β mRNA significantly increased and COL6 remained 
unaltered in HSC-10 compared to HSC-1 at 2 h (Fig. 2F). 
All these results indicate that the presence of 10% FBS 
medium enhances the pro-inflammatory phenotype and 
only partially that pro-fibrogenic.
LPS induces LITAF expression/activity in 
primary mouse activated HSCs
The liver exposure to gut-derived microbial 
products, such as LPS, and the resulting activation 
of TLR-4 signalling in HSCs is now emerging as 
one of the key event in NAFLD-related fibrosis and 
inflammation [29, 30]. In order to investigate whether 
endotoxin may exacerbate LITAF expression and/
or nuclear translocation we treated primary mouse 
HSC-1 and HSC-10 with two different concentrations 
of LPS (100 or 500 ng/ml) at different timepoints (1, 2 
and 3 h). Our results demonstrated that the highest 
concentration of LPS (500 ng/ml) significantly increased 
LITAF mRNA levels (Fig. 3A) both in HSC-1 and HSC-
10 early after 1 h of treatment, accordingly to an up-
regulation of LITAF protein expression observed at 3 h 
(Fig. 3B). However, confocal laser microscopy (Fig 3C) 
highlighted that both LPS concentrations induced a 
significant increase of LITAF nuclear translocation, 
accompanied by a concomitant rise in α-SMA expression 
after 2 h from treatment either in HSC-1 or in HSC-10. 
These results were confirmed by quantitative imaging 
data and highlighted that nuclear translocation of LITAF 
increased mainly in HSC-10 as early as 1 h after LPS 
addition (Fig. S3A).
In macrophages, LPS is the main factor activating 
LITAF transcriptional activity of different cytokines, 
particularly TNF-α [17]. Therefore, we next analysed 
the LPS effect on autocrine production of a wide array 
of cytokines. The array profile showed LPS-induced 
production of several cytokines (Fig. S3B). Particularly, 
after 3 h treatment, LPS caused a significant up-
regulation of IL-1β, IL-6 and TNF-α production with 
respect to untreated cells in both HSC-1 and HSC-10 
(Fig. 3D). Furthermore, we found that LPS treatment 
caused an increase of α-SMA and TGF-β gene expression 
(Fig. S3C and S3D). Whereas other pro-fibrogenic genes, 
such as COL1 and COL6, were fluctuating depending on 
LPS dose and time exposure (Fig. S3E and S3F).
LPS-dependent pro-inflammatory phenotype 
in human HSCs is mediated by LITAF 
transcriptional activity
In light of the previously reported evidence, we 
examined the LPS-dependent LITAF expression and 
distribution in LX-2 HSC cell line. This cell line, that has 
been extensively validated for its similarities to human 
culture activated HSCs, presents a higher efficiency 
of transfectability and expression of ectopic genes and 
silencing than primary HSCs [31]. In detail, we stimulated 
LX-2 cells with different dosages of LPS (100 or 500 ng/ml) 
at different timepoints (1, 2, 3 and 24 h). Coherently 
with the results obtained in primary mouse HSCs, LITAF 
protein was more abundant into the nucleus of LX-2 cells 
early after 1 h and peaked at 2 h from LPS stimulation 
with respect to the untreated counterpart (Fig. 4A and 
Fig. S4A) as also confirmed by a quantitative analysis of 
imaging data (Fig. 4B). As observed in primary mouse 
HSCs, total LITAF mRNA significantly increased after 3 h 
from LPS stimulus, either at 100 or 500 ng/ml (Fig. 4C). 
Interestingly, we also reported that LPS inhibited LX-2 
cell proliferation measured as BrdU incorporation at 
24 h (Fig. S4B). Considering the LPS-dependent pro-
inflammatory and pro-fibrogenic phenotype observed 
in primary mouse HSCs, we further analyzed in LX-2 a 
panel of cytokines and various well-established molecular 
markers of transdifferentiation. In order to delineate the 
modulation of each target gene along the time we exposed 
LX-2 cells to LPS within a time window from 1 h to 
3 h. We reported a significant up-regulation of IL-1β and 
IL-6 transcripts, especially after 3 h from LPS stimulus, 
compared to untreated cells (Fig. 4D and 4E); whereas a 
LPS-dependent increase of TNF-α mRNA levels occurred 
at early time (1 h) (Fig. 4F). Furthermore, differently 
from what observed in primary mouse HSCs we found 
that α-SMA and COL1 mRNA levels remained unaltered 
under LPS addition (Fig. S4C), whereas TGF-β and COL6 
mRNA levels were significantly increased by 500 ng/ml 
LPS after 1 h of exposure (Fig. 4G).
Based on CTCCC repeats, the already described 
LITAF responsive element within TNF-α promoter 
[16], we designed specific primers for each cytokine 
promoter (Fig. S5A). Noteworthy, the results of 
chromatin immunoprecipitation (ChIP) indicated 
that LITAF specifically binds the promoter of all the 
three crucial pro-inflammatory genes, namely IL-1β, 
IL-6 and TNF-α. In particular, LITAF displayed a more 
pronounced binding to these promoters just after 2 h 
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Figure 3: LPS increases LITAF and pro-inflammatory markers expression in HSC-1 and HSC-10. A–D. Isolated HSC 
were cultured for 5 days in medium supplemented with 10% FBS and then serum starved for additionally 24 hours. Cells were then 
stimulated with LPS (100 and 500 ng/ml) in the presence of either 1% (HSC-1) or 10% (HSC-10) FBS. Cells were then collected at 
different timepoints. A: QRT-PCR analysis of LITAF mRNA expression (n = 3). B: Immunoblot analysis of total LITAF at 3 h (data 
presented is representative of three independent experiments). C: Representative confocal imaging of α-SMA (blue), LITAF (red) and 
nuclei (white), and X- and Y-axis projections of Z-reconstructions (right column) of α-SMA/LITAF double-stained cells at the level of 
LITAF nuclear localization after 2 h of LPS treatment. Nuclei were counterstained with DRAQ5 (scale bar: 50 μm). D: Semi-quantitative 
protein expressions of IL-1β, IL-6 and TNF-α in total cell lysate of HSC-1 and HSC-10 after 3 h by using a Cytokine Antibody Array 
(n = 2). Histograms represent the mean ± SD. Differences across groups were analysed by ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001.
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from LPS stimulation (Fig. 5A). To investigate if IL-6, 
TNF-α and IL-1β are truly LITAF-targeted transcripts, 
LX-2 cells were transduced with either LITAF shRNA 
or nonspecific scRNA lentiviral plasmid. Next, cells 
were maintained in the presence of puromycin for more 
than 4 weeks for the establishment of stable silenced 
and control cell lines. The stable expression of LITAF 
shRNA caused a reduction of approximately 70% 
and 90% of LITAF protein and mRNA, respectively 
(Fig. S5B). Moreover, we found that the delivery of 
LITAF shRNA in LX-2 cells significantly reduced 
IL-1β and IL-6 mRNA expression (Fig. 5B), but 
unaffected the levels of TNF-α, α-SMA, TGF-β, COL1 
and COL6 transcripts (Fig. S5C), as well as platelet-
derived growth factor receptor (PDGFR)-β mRNAs 
(Fig. S5D). Interestingly, LITAF silencing reduced the 
100 ng/ml LPS-induced IL-1β and IL-6 mRNAs after 
3 h (Fig. 5C and 5D). Diversely, 500 ng/ml LPS was 
ineffective to produce similar reduction, probably due to 
a partial recovery of LITAF mRNA (Fig. 5E).
All this data confirmed that LITAF silencing 
can effectively interfere with the transcription of pro-
inflammatory genes in HSC cell lines. We also reported a 
down-regulation of α-SMA protein expression in LITAF-
silenced LX-2 cells compared to control (Fig. S5E), and 
the inability of LPS to recover this effect (Fig. S5F).
Figure 4: LPS induces LITAF nuclear translocation and inflammatory and fibrotic responses in LX-2 cells. A–G. LX-2 
cells with (LPS 100 and LPS 500) or without (NT) LPS treatment. A: Immunoblot analysis of cytosolic and nuclear LITAF after 1 h and 2 h 
from LPS treatment (data presented is representative of three independent experiments). B: Quantitative imaging analysis of LITAF nuclear 
translocation after 2 h from LPS addition. Mann-Whitney U test. C-G: QRT-PCR analyses of (C) LITAF, (D) IL-1β, (E) IL-6, (F) TNF-α 
and (G) TGF-β and COL6 mRNA after 1 h, 2 h and 3 h from LPS stimulus (n = 3). Histograms represent the mean ± SD. Differences across 
groups were analysed by ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT.
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p38MAPK is an upstream factor for LITAF 
nuclear translocation and activity
Tang et al. [17] identified the TLR-4-dependent 
p38 mitogen-activated protein kinase (p38MAPK) as 
the responsible of LITAF phosphorylation/activation 
and nuclear translocation both in monocytic cells and 
in mouse macrophages. Hence, we investigated the 
p38MAPK expression and activation in LX-2 cells 
before and after the LPS treatment. We found that the 
expression of total p38MAPK was unaffected, whereas 
Thr180/Tyr182 phosphorylated form was significantly 
increased by LPS within 45 minutes of treatment 
(Fig. 6A). Furthermore, immunoprecipitation analysis 
showed that after 45 minutes from LPS addition 
the binding of LITAF to p38MAPK and its serine 
phosphorylation increased (Fig. S6A). As expected, 
SB203580, a specific inhibitor of p38MAPK, abolished 
LITAF nuclear translocation. After inhibitor dosage 
titration (data not shown), we found that only 30 μM 
SB203580 pre-treatment for 30 minutes reduced 
LPS-dependent LITAF nuclear translocation at 2 h in 
LX-2 cells (Fig. 6B and Fig. S6B).
To confirm the role of p38MAPK as upstream 
factor regulating LITAF-dependent transcriptional 
activity on pro-inflammatory genes we performed qRT-
PCR analyses. We found that SB203580 reduced the 
mRNA expression of both IL-1β, IL-6 and TNF-α under 
LPS addition (Fig. 6C–6E). This evidence was coupled 
with the SB203580 inhibitory effect on LITAF nuclear 
translocation and on LITAF binding to IL-1β, IL-6 and 
TNF-α promoters (Fig. S6C), supporting the pivotal 
role of nuclear LITAF as pro-inflammatory transcription 
factor. We also found that both concentrations of 
LPS caused a significant increase of TLR-4 mRNA 
(Fig. S6D). Moreover, the p38MAPK inhibition by 
SB203580 reduced LPS-dependent increase of TLR-4 
transcription (Fig. S6E). The latter result suggests that 
nuclear translocation of LITAF could be mediated by 
LPS/TLR-4-activated p38MAPK.
Figure 5: LITAF binds and regulates IL-1β and IL-6 promoters. A. LX-2 cells were exposed for 2 and 3 h to 100 ng/ml and 
500 ng/ml LPS. Input, mock and mouse anti-RNA Pol II antibody were used as ChIP control. LITAF immunoprecipitated was used for 
the amplification by qPCR of IL-1β, IL-6 and TNF-α promoters. Input DNA was used to assess GAPDH transcript for normalization (data 
presented are representative of three independent experiments). B. QRT-PCR analysis of IL-1β and IL-6 in control (siCTRL) and LITAF-
silenced (siLITAF) LX-2 cells. C–E. siCTRL and siLITAF LX-2 cells treated with 100 ng/ml and 500 ng/ml LPS. QRT-PCR of IL-1β (C), 
IL-6 (D) and LITAF (E) mRNA in the presence of LPS at 3 h (n = 3). Histograms represent the mean ± SD. ***p < 0.001 for comparison 
between siCTRL and siLITAF cells, Student’s t test.
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LITAF functionally and physically interacts with 
NF-ĸB to regulate some pro-inflammatory genes
In order to define if the inhibitory effects 
of SB203850 on LPS-induced IL-1β, IL-6, TNF-α and 
TLR-4 transcription could be exclusively associated 
to LITAF activity or if it could be the result of LITAF 
interaction with the master pro-inflammatory transcription 
factor NF-ĸB, we performed in vitro experiments on 
LX-2 cells with sulfasalazine (SZA). This drug blocks 
Figure 6: p38MAPK and p65NF-ĸB role in LITAF nuclear translocation and activity. A. Immunoblot analyses showing the 
expression of Thr180/Tyr182 phosphorylated form (pp38) and total form (p38) of p38MAPK in LX-2 cells under 100 ng/ml and 500 ng/ml 
LPS treatment for 15, 45 and 60 minutes (data presented are representative of three independent experiments). B. Immunoblot analysis of 
cytosolic and nuclear LITAF after 30 minutes of SB203850 pre-treatment followed by 2 h of 100 ng/ml and 500 ng/ml LPS exposure (data 
presented is representative of three independent experiments). C–E. QRT-PCR analyses of IL-1β (C), IL-6 (D) and TNF-α (E) mRNA after 
30 min of SB203850 pre-treatment followed by 3 h of 100 ng/ml and 500 ng/ml LPS exposure (n = 3). Histograms represent the mean ± SD. 
**p < 0.01, ***p < 0.001 vs. vehicle (DMSO), Student’s t test. F–H. QRT-PCR analyses of IL-1β (F), IL-6 (G) and TNF-α (H) mRNA 
in LX-2 cells under LPS 100 ng/ml exposure pre-treated or not with single SB203850 and SZA or in combination (n = 3). Histograms 
represent the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 vs. vehicle (DMSO or Methanol), Student’s t test. I. Representative confocal 
imaging of p65NF-ĸB (green), LITAF (red) and nuclei (blue) after 2 h from LPS treatment of LX-2 cells pre-treated or not with SB203850 
(n = 3). J. Representative (n = 2) immunoprecipitation between LITAF and p65NF-ĸB. β-actin was probed as loading control.
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NF-ĸB-dependent transcription at micro- to milli-molar 
concentrations by the inhibition of IĸBα degradation 
[32]. We pre-treated LX-2 cells with 0.5 mM SZA, which 
inhibited LPS-induced NF-ĸB nuclear translocation 
(Fig. S6F). The same SZA concentration, alone or 
in combination with 30 μM SB203850, was used to 
treat LX-2 cells before 100 ng/ml LPS addition. We 
demonstrated that IL-1β transcription was down-sized 
only by p38MAPK inhibitor (Fig. 6F), whereas IL-6 
and TNF-α transcripts were mainly de-regulated by 
SB203850 with a minor effect of SZA (Fig. 6G and 6H). 
These results suggested that all the analysed cytokines 
could be mainly regulated by p38MAPK potential effects 
on LITAF activity and other downstream factors, such 
as the same p65NF-ĸB. Noteworthy, we found that, 
although p38MAPK inhibitor prevented LPS-induced 
nuclear translocation of LITAF, it was concurrently almost 
ineffective on that of p65NF-ĸB (Fig. 6I). Nevertheless, 
a functional and physical interaction between LITAF and 
p65NF-ĸB cannot be not excluded. In fact, siLITAF LX-2 
cells under 100 ng/ml LPS exposure expressed a strongly 
reduced amount of p65NF-ĸB into the nucleus with respect 
to siCTRL counterpart (Fig. S6G). Moreover, we found 
that LITAF and p65NF-ĸB co-precipitated, and that this 
interaction was moderately susceptible to LPS addition 
(Fig. 6J). Further experiments are needed to elucidate the 
potential mechanisms involved in this cross-talk.
Circulating levels of IL-1β correlate with LPS, 
the number of LITAF-positive HSCs and 
inflammation in paediatric patients with NAFLD
The activation of a chronic low-grade inflammation 
in NAFLD patients occurs in liver-resident cells, often 
reflecting tissue damage severity [33]. Therefore, we 
next set out to assess if circulating levels of LPS and 
cytokines correlated with LITAF expression in HSCs and 
histological features of NASH.
Plasma levels of IL-1β, IL-6, TNF-α and LPS were 
analysed in 40 children (male/female ratio 27:13) with 
biopsy-proven NAFLD and 8 controls (male/female 
ratio 5:3). The mean age of NAFLD patients was 
12.0 years ± 2.6 (SD) and the mean body mass index 
(BMI) was 29.4 kg/m2 ± 10.6. Plasma levels of IL-1β, 
IL-6, TNF-α and LPS were significantly increased 
(p < 0.001) in NAFLD children as compared to the age-
matched control subjects (Fig. S7A–S7D).
Next, the correlations between circulating levels 
of IL-1β, IL-6, TNF-α and LPS, the number of LITAF-
positive HSCs and the histological pattern of disease were 
assessed. The plasma levels of IL-1β were significantly 
correlated with those of LPS (Pearson’s r = 0.62, 
p < 0.001), with the number of LITAF-positive HSCs 
(Pearson’s r = 0.31, p < 0.05) and with inflammation 
(Pearson’s r = 0.48, p < 0.01). Interestingly, the number of 
LITAF-positive HSCs significantly correlated (Fig. S7E) 
not only with IL-1β levels but also with inflammation 
(Pearson’s r = 0.34, p < 0.05) and fibrosis (Pearson’s 
r = 0.69, p < 0.001) and with the presence of NASH 
(Pearson’s r = 0.66, p < 0.001). Further correlation data are 
also reported (Fig. S7E). Moreover, our data revealed that 
circulating levels of IL-1β were significantly (p < 0.001) 
increased in children with I ≥ 2 compared to subjects with 
I ≤ 1 (Fig. 7B). No statistically significant differences 
in IL-1β plasma levels were found to be in relation with 
steatosis grade (Fig. 7A), ballooning and fibrosis severity 
(Fig. 7C and 7D) and comparing NASH vs. NotNASH 
group (Fig. 7E). Interestingly, we also found that IL-1β 
levels in plasma correlated with those expressed in the 
liver (Pearson’s r = 0.66, p < 0.01).
Finally, multinominal regression analysis revealed: 
in model 1 (Fig. 7F, upper panel) that plasma levels of 
IL-1β were significantly associated with inflammation, 
while the other variables, including IL-6, TNF-α, LPS 
and the number of LITAF-positive HSCs, were dropped 
as not significant; in model 2 (Fig. 7F, lower panel) that 
the IL-1β plasma levels were significantly associated 
with fibrosis, and forward stepwise inclusion of LPS 
and LITAF-positive HSC number variables positively 
influenced odds ratios.
DISCUSSION
In this study, we show that LPS induces several pro-
inflammatory cytokines via activation of LITAF in HSCs, 
resulting in a pattern of inflammation and fibrosis that may 
be responsible for a part of the tissue damage in NASH 
(Fig. 8). This is the first report to demonstrate that LITAF 
may be crucial in NAFLD pathogenesis by driving HSC 
responsivity to LPS.
The NAFLD has become the most common chronic 
liver diseases in both children and adults [34, 35]. 
NAFLD conditions range from simple steatosis to NASH, 
characterized by the presence of necrosis, inflammation 
and eventually fibrosis. The molecular mechanisms 
involved in the pathogenesis of NAFLD still remain 
unclear [36–41]. Previous studies suggest a plausible role 
for the gut-liver axis and of intestinal bacterial products, 
such as LPS, in NAFLD-related liver damage [42–46]. 
HSC activation is a key event in NAFLD, accounting for 
inflammatory molecule production and being the major 
player for matrix deposition during fibrogenesis [22, 26, 
27, 30, 47, 48]. It is well known that HSCs express TLR-4, 
which, interacting with its principal ligand LPS, initiates a 
signalling cascade culminating in a pro-inflammatory and 
pro-fibrogenic response [49, 50]. Several lines of evidence 
have demonstrated that low-to-high doses of LPS induce 
synthesis and release of pro-inflammatory cytokines in 
human and rodent models of quiescent and transitionally 
activated HSCs [7, 51–53].
We previously demonstrated a strong correlation 
between increased circulating levels of both LPS and 
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TNF-α and liver damage in paediatric patients with 
NAFLD [5]. We also reported a significant alteration 
in protein/mRNA expression levels of LITAF in rats 
with diet-induced NAFLD [19]. Here we show that an 
increased expression of LITAF protein in parenchymal and 
non-parenchymal liver correlates with the severity of the 
disease in children with NAFLD, confirming our previous 
data in the rat model. Furthermore, we observed that 
hepatocellular LITAF over-expression occurs mainly at 
the interface with the fibrotic area where α-SMA reaches 
its maximal expression. The reasons of this phenomenon 
recall further exploration. This finding suggests that LITAF 
may play an important role in determining liver damage in 
NAFLD. In particular, the upsized intra-hepatic expression 
of LITAF was observed in subjects that displayed a more 
severe pattern of inflammation and fibrosis. Although all 
liver-resident cells are involved in the development of 
NAFLD and its progression to NASH, activated HSCs 
are the main cell type responsible for fibrogenesis in 
the liver. Activated HSCs are known to produce several 
pro-inflammatory mediators that contribute to maintain 
themselves activated and capable of exacerbating hepatic 
fibrosis and inflammatory milieu [23]. Therefore, here we 
tried to dissect the role of LITAF in the pro-fibrogenic and 
pro-inflammatory phenotype of HSCs. Our data indicates 
that LITAF can be an LPS-induced pro-inflammatory and 
pro-fibrogenic mediator during NASH development and 
suggests that this transcription factor contributes to the 
liver damage caused by HSC activation. Interestingly, 
LITAF is mostly nuclear in activated HSCs suggesting a 
switch on of its transcriptional activity in these cells as 
demonstrated by Tang et al in macrophages [17]. It is 
well established that the status of HSC activation and its 
maintenance rely on the presence of different cytokines 
[54]. Our data shows that the maintenance of a serum-
dependent activation state in HSCs is characterized by 
an enhanced repertoire of pro-inflammatory cytokines 
and chemokines of which IL-1β, IL-6 and TNF-α have 
been the focus of major interest. Mouse HSCs were found 
to produce these and other cytokines and chemokines 
under LPS stimulation. Using an extensive assortment 
of cytokines allowed us to confirm and amplify the pro-
inflammatory response to LPS [7, 52]. Analysis of the 
LPS-induced pro-inflammatory and pro-fibrogenic pattern 
in LX-2 cells, which is the best characterized model of 
in vitro HSCs, has highlighted a similarity with primary 
mouse HSCs in concert with an up-regulation of LITAF 
transcription and expression into the nucleus. Our results 
are in agreement with previous data [52] showing the 
ability of LPS to promote pro-inflammatory more than pro-
fibrogenic genes, and its anti-proliferative effect. We found 
within the IL-1β and IL-6 promoters, a LITAF consensus 
sequence (CTCCC) already identified in TNF-α [16]. 
ChIP analysis confirms the LPS-dependent increase of 
LITAF binding to IL-1β, IL-6 and TNF-α promoter region. 
Furthermore, we provide the first evidence that LITAF 
silencing in LX-2 HSCs reduces expression of both IL- 1β 
and IL-6 mRNAs but has no effect on TNF-α mRNA. 
Figure 7: Circulating IL-1β acts as descriptor of inflammation and fibrosis in paediatric patients with NAFLD. A–E. 
Scatter dot plots of plasma levels of IL-1β with respect to (A) steatosis grade (S = 1, S = 2, S = 3); (B) inflammation (I ≥ 2 vs. I ≤ 1); 
(C) ballooning (B ≥ 1 vs. B = 0); (D) fibrosis (F ≥ 2 vs. F ≤ 1); and (E) the presence of NASH (n = 40). Mean value ± SD. ***p < 0.001. 
Mann-Whitney U test. F. Odds ratios for inflammation (model 1) and fibrosis (model 2). The analyses was performed by including IL-1β 
IL-6, TNF-α, LPS and LITAF-positive HSCs.
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Moreover, LITAF silencing is detrimental for low-dose 
LPS-mediated induction of IL-1β and IL-6 transcripts, 
indicating that they are LITAF-dependent genes in 
HSCs activated towards a pro-inflammatory phenotype. 
Interestingly, in the same cells, LITAF silencing also 
affects the α-SMA protein expression suggesting no 
transcriptional activity effect but plausibly other post-
translational regulatory mechanisms. Because endosomal 
fraction of LITAF interacts with ubiquitin ligases 
sequestering them into the lysosomes (e.g. Itch) [53], and 
given that α-SMA is described as one of the ubiquitinated 
proteins (mUbiSiDa: http://222.193.31.35:8000/detail_
info.php?name=Q13707), LITAF depletion may enhance 
targeted proteins degradation. Accordingly, we found an 
up-regulation of ubiquitin expression in siLITAF cells 
(data not shown), but this mechanism requires further 
experimental exploration.
Thirunavukkarasu et al [54] have demonstrated 
that endotoxin-induced expression of TNF-α and IL-6 in 
HSCs is initiated by the p38MAPK and is mediated by 
NF-ĸB. However, p38MAPK, recognized as an upstream 
factor of LPS/TLR4/MyD88 signalling cascade, has been 
reported to regulate nuclear translocation and activity 
of pro-inflammatory transcription factors, including 
AP-1 and LITAF [17, 55]. Our data confirms an early 
activation of p38MAPK and its physical interaction with 
LITAF in LPS-treated LX-2 cells. The major role of LPS-
activated p38MAPK on LITAF activity is validated by 
the inhibitory effects of SB203850 on LITAF nuclear 
translocation and transcriptional activity. The use of 
SB203850, alone or in combination with the NF-ĸB 
inhibitor SZA, allows us to exclude the possibility that 
p65NF-ĸB has a role in the regulation of IL-1β promoter, 
but does not rule out its potential cooperation with LITAF 
Figure 8: Schematic representation of LPS-induced LITAF transcription role in HSCs during NAFLD. Activation of 
TLR-4 through binding of LPS leads to receptor dimerization and the recruitment of adaptor proteins, such as MyD88. This triggers the 
engagement of several other protein complexes resulting in the activation of TAK1. Once activated TAK1 may promote: 1) phosphorylation 
and activation of p38MAPK which supports the LITAF-dependent production of IL-1β and IL-6; 2) nuclear translocation and activation 
of p65NF-ĸB which regulates the production of TNF-α. SB203580 may hamper p38MAPK activation resulting in the inhibition of LITAF 
phosphorylation, nuclear translocation and transcriptional activity.
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in regulating IL-6 and TNF-α gene transcription. In fact, 
we demonstrated a physical interaction of LITAF with 
p65NF-ĸB in LX-2 cells.
The discovery that LITAF is a main regulator 
of IL-1β in HSCs could provide a new mechanism that 
may improve both our understanding of how NAFLD-
related liver damage (i.e. inflammation and fibrosis) 
develops, and the design of novel therapeutic approaches. 
In fact, Kamari et al recently demonstrated [56] that 
IL-1β selective deficiency in liver parenchymal cells 
protected mice from diet-induced NASH and fibrosis. The 
relevance of this novel LPS/TLR-4/LITAF signalling in 
regulating potential development of hepatic inflammation 
and fibrosis that characterizes NASH is emphasised by 
the fact that children affected by this disease frequently 
display also a pattern of low-grade systemic inflammation. 
Furthermore, plasma levels of IL-1β avatar the mRNA 
hepatic expression of the same cytokine, suggesting a 
relevant contribution of liver cells to systemic increase 
of this inflammatory molecule. From a mechanistic 
viewpoint, these results suggest that LPS/LITAF pathway, 
regulating IL-1β production, may interact with the NLRP3 
inflammasome complex that, sensing LPS, may induce 
IL-1β maturation [57, 58]. From a translational point 
of view, circulating and hepatic IL-1β, which associate 
to LPS and LITAF-positive HSCs, may outline a panel 
of potential biomarkers of more severe inflammation 
and fibrosis in children with NAFLD. Furthermore, in 
this setting it is conceivable that a targeted approach for 
preventing LITAF activity could mitigate NAFLD-related 
liver damage by reducing both hepatic and systemic 
IL-1β production/release. Unfortunately, currently no 
direct antagonist of LITAF activity exist, while several 
pharmaceutical companies have developed p38MAPK 
inhibitors for therapeutic use. Some of these drugs are in 
phase I and phase II clinical trials [59] and our findings 
suggest that they may virtually improve liver damage in 
patients with NASH.
In conclusion, the discovery of LITAF as a key 
regulator of pro-inflammatory and pro-fibrogenic 
response in HSCs provides new insights in the molecular 
pathogenesis of NAFLD-related damage. It also raises 
a series of provocative questions about the cell-to-cell 
communication “in and outside” the liver in patients with 
NAFLD, suggesting that IL-1β could be a common trigger 
for both progression of liver disease and development of 
co-morbidities.
MATERIALS AND METHODS
Human subjects and liver histology
Cohort 1 included 8 children with no evidence 
of fatty liver at ultrasonography and subjected to 
appendicectomy. Liver tissues from these patients 
were used for immunohistochemical/immunofluorescent 
analyses. Cohort 2 included 25 children with biopsy-proven 
NAFLD. Cryopreserved liver tissues from these patients 
were used for molecular analyses. Cohort 3 included 
Cohort 2 samples and further 15 liver samples from 
children with biopsy-proven NAFLD. Blood samples 
and liver specimens (paraffin-embedded tissues) from 
these patients were used for the analysis of circulating 
markers and immunofluorescence. Cohort 4 included 
Cohort 1 samples and further 17 liver samples from 
children without liver disease. All samples were collected 
at the Hepato-Metabolic Disease Unit of the Bambino 
Gesù Children’s Hospital between March 2013 and 
September 2014. Main inclusion criteria were complete 
abstinence from alcohol and the absence of other liver 
diseases. Diagnosis of NAFLD was performed on bioptic 
samples, fixed in 10% buffered formalin and processed for 
hematoxylin and eosin staining and Masson’s trichrome 
staining. Grade and stage of disease were assessed by the 
NAFLD Clinical Research Network criteria [21].
Animals and HSC isolation
Adult, male Balb/c mice were provided by 
Dr. Svegliati Baroni’s Lab (Ancona, Italy). The animals 
were permitted ad libitum consumption of water and 
standard rodent food. Upon completion of 8 weeks of 
treatment, mice were killed and primary mouse HSCs 
isolated from normal liver. The isolation procedure was 
performed by collagenase-pronase perfusion technique 
followed by density gradient centrifugation on Nycodenz 
gradients as described previously [41]. After purity and 
viability check, the isolated cells were seeded on plastic 
dishes and chamber slides at a density of 2 × 105/ml and 
cultured in DMEM supplemented with 10% foetal bovine 
serum (FBS) and penicillin/streptomycin as described 
previously. Cells were cultured for 5 days in medium 
supplemented with 10% FBS and then serum starved for 
additionally 24 hours. Cells were then stimulated with 
LPS (100 and 500 ng/ml) in the presence of either 1% 
(HSC-1) or 10% (HSC-10) FBS. Cells were then collected 
at different timepoints (1, 2, 3, and 6 h).
Human LX-2 cell line
The human LX-2 cell line, purchased by Merck 
Millipore (Germany), were seeded into 6-well plates 
with 105 cells per well in DMEM supplemented with 
10% FBS, 2 mM L-glutamine, 100 units/ml penicillin, 
and streptomycin at 37°C in 5% CO2. At about 60–70% 
confluence two different concentrations of LPS (100 or 
500 ng/ml) were added to the medium and cells were 
harvested at different timepoints (15 and 45 min, 1, 2, 
3, 6 and 24 h) from the treatment. PBS was added as 
vehicle control. When requested, a 30 min pre-treatment 
was performed before the LPS stimulus with 30 μM 
SB203580 (Sigma-Aldrich Inc. MO, USA) and/or 0.5 mM 
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sulfasalazine (Sigma-Aldrich Inc. MO, USA). DMSO and/
or Methanol were added as vehicle controls.
Lentiviral shRNA silencing of LITAF in 
LX-2 cells
Lentivirus-delivered stable silencing was carried 
out on LX-2 cells seeded in 6-well plates at 80% 
confluence. Cells were incubated with the lentiviral 
particles (multiplicity of infection, MOI= 4) in presence 
of hexadimethrine bromide (8 μg/ml). Lentiviral 
particles used for LITAF silencing were Mission 
shRNA TRCN0000297833 and TRCN0000280440 
(SHCLNV,Sigma-Aldrich Inc. MO, USA). As a control, 
LX-2 cells were also transduced with viral particles 
(MOI = 4) containing non-targeting shRNA, namely 
MISSION® pLKO.1-puro Non-Target shRNA Control 
Transduction Particles (SHC002V, Sigma Aldrich Inc. 
MO, USA). Transduced cells were selected in complete 
growth medium containing puromycin (5 g/ml). The 
silencing efficiency was monitored both by qRT-PCR and 
immunoblot analysis.
Immunofluorescence
Immunofluorescence was performed on 2 μm 
sections of paraffin-embedded liver tissue and on LX-2 
and primary mouse HSCs seeded on 4-well chamber 
slides and fixed in cold methanol/acetone (2:1). The 
slices were incubated with primary antibodies (listed 
in Table S1). Detection of the primary antibodies was 
performed using 1:500 Alexa Fluor® conjugated secondary 
antibodies (Invitrogen/Molecular Probes Corp, CA, USA). 
The images were captured and analyzed using Olympus 
FluoView FV1000 confocal microscope. The images were 
acquired using an identical acquisition time for all tissue 
sections.
Double staining: Immunohistochemistry and 
immunofluorescence
Immunostaining of formalin-fixed paraffin-
embedded tissue specimens was performed on 2 μm 
sections. After dewaxing and rehydrating, heat-induced 
epitope retrieval was performed by boiling the slides 
with Dako Target Retrieval Solution pH 8 (10X). 
Endogenous peroxidase was blocked with 3% hydrogen 
peroxide followed by incubation with avidin/biotin 
blocking system (Thermo Scientific, IL, USA) to inhibit 
endogenous biotin activity. We used primary polyclonal 
rabbit antibodies raised against LITAF. Staining was 
performed with Dako Envision Plus System (Dako 
Cytomation, Italy). Once developed the staining for 
LITAF by 3, 3′-diaminobenzidine (DAB) Substrate 
(Vector Laboratories, CA, USA), the double staining was 
performed by a second labeling via immunofluorescence 
technique. The slides were incubated again for 1 h with 5% 
BSA to block eventual non-specific sites. Subsequently, the 
sections were incubated with the second primary antibody, 
the mouse monoclonal α-SMA diluted in 5% BSA in PBS, 
at +4°C overnight. A secondary antibody anti-mouse Alexa 
Fluor® 488 dye (1:500, Life Technologies, CA, USA) was 
used. The nuclear staining was carried out by 5 minutes 
incubation with 2′-(4- hydroxyphenyl)-5-(4-methyl-1-
piperazinyl)-2, 5′-bi-1H-benzimidazole dihydrochloride 
hydrate (Hoechst) (Sigma-Aldrich Inc. MO, USA) diluted 
1:10000 in 1X PBS. The slides were finally mounted 
with aqueous base 60% glycerol. For primary antibodies 
details, see Table S1. Confocal imaging was performed 
using an Olympus Fluoview FV1000 confocal microscope 
equipped with FV10-ASW 2.0 software, Multi Ar 
(458–488 and 515 nm), 2X He/Ne (543 and 633 nm), 
405-nm diode lasers and a 60x 1.42 oil objective. Optical 
sections were acquired with a format of 1024 × 1024 
pixels, a sampling speed of 40 μs/pixel, and 12 bits/
pixel images. Fluorochrome unmixing was performed by 
automated-sequential collection of multi-channel images 
to reduce spectral cross-talk between channels.
Automatic quantification and comparison of 
nuclear LITAF concentration
In total, images from 253 slides were acquired with 
the Olympus Fluoview FV1000 confocal microscope 
at 400x resolution, and stored as 32 bit RGB images of 
1024 × 1024 pixels. Each image includes the two levels 
(channels) corresponding to nucleus and LITAF staining.
A computational pipeline was developed to quantify 
the amount of LITAF within cell nuclear regions in the 
digitalized images (Fig. S2A). The pipeline first localizes 
nuclear regions in the nuclear-stained channel (steps 1–6), 
and then estimates the nuclear LITAF concentration by 
considering the intensity in the LITAF staining channel 
of the pixels within the nuclear regions localized in the 
nuclear-stained channel (step 7).
More in details, cell nuclei are localized by applying 
the following procedure. Images are first preprocessed 
with the Otsu thresholding algorithm [60] to remove 
the background noise (step 1). To take into account the 
differences in illumination and staining across the slides, 
which would bias the standard Otsu thresholding leading 
to false negatives in the detection of nuclei, we applied 
a local Otsu method. Briefly, each image was divided in 
a grid of nine blocks, and the Otsu method was applied 
independently within each block, producing a (potentially) 
different threshold for each block. Then, a pixel-by-pixel 
local threshold was calculated as the average of the nine 
thresholds, weighted by the distance from the centroid of 
each block to the pixel.
After thresholding, the gaps within nuclear 
regions were filled by convolving each thresholded 
image with a Gaussian diffusion process (step 2), 
and applying the erosion morphological operator to 
the result of the convolution (step 3). This procedure 
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also removes the skewness from nuclear borders. The 
Watershed algorithm [61] was then used to segment the 
resulting image and localize each nucleus (steps 4–5). 
Finally, a post-processing step was applied to removing 
segmented regions that were too small to represent 
nuclei (step 6).
For each nucleus, the median of the corresponding 
pixel intensity in the LITAF staining channel was used 
as estimate of the nuclear LITAF concentration (step 7). 
For each biological sample, the median of the nuclear 
LITAF concentration of all the nuclei was considered as 
nuclear LITAF concentration index. The computational 
pipeline has been implemented in Python 2.7, relying on 
morphological operators and watershed algorithms from 
the Mahotas library [62].
RNA isolation and Quantitative Real-time PCR
Total RNA was isolated from cells using TRIzol 
(Invitrogen, Carlsbad, CA, USA) and from liver tissues 
by RNA Purification Plus Kit (Norgen Biotek Corporation, 
ON, Canada) following manufacturers’ instructions. 
cDNA was synthesized by High Capacity cDNA Reverse 
Transcription Kits (Applied Biosystems, Foster City CA, 
USA) according to kit’s instructions. Quantitative Real-
Time (qRT-PCR) amplification, detection and analysis 
was performed by ABI Prism 7900HT Fast Real-Time 
PCR System (Applied Biosystems, Foster City CA, USA) 
using TaqMan® Fast Universal PCR Master Mix (2X) 
No AmpErase® UNG (Applied Biosystems, Foster City 
CA, USA). GAPDH housekeeping gene was used as a 
reference control for normalization. Based on the ΔΔCt 
method, relative amounts of mRNA were expressed as 
fold changes versus controls. Primer references are listed 
in Table S2.
Immunoprecipitation and western blotting
Cells were collected and lysed with Ripa Buffer. 
Whole cell extracts were quantified using the BCA™ 
Protein Assay (Thermo Scientific, IL, USA). For 
immunoprecipitation, approximately 0.5 mg of the lysate 
protein was immunoprecipitated using 1 μg of rabbit 
polyclonal anti-LITAF antibody (sc-66945 Santa Cruz 
Biotech. CA, USA) at 4°C overnight and next incubated 
with protein A/G-agarose (Santa Cruz Biotech. CA, USA) 
at 4°C for 1 h. Whole lysates and eluates were prepared 
in sample buffer and separated by SDS-PAGE resolving 
gels. Proteins were electrophoretically transferred to 
Hybond-C Extra membranes (Amersham, Germany) and 
incubated firstly with primary antibodies, then with HRP-
conjugated secondary antibody (Santa Cruz Biotech. 
CA, USA) following standard methods [63]. Protein 
expression was quantified by densitometry analysis using 
Image J v3.91 software. For primary antibodies details, 
see Table S1.
Cytokine protein array analysis
Mouse Inflammation Antibody Array C1 (Cat# 
AAM-INF-1) purchased from RayBiotech, Inc. (Norcross, 
GA, USA) was employed to evaluate the expression 
of 40 different cytokines in cell lysates from primary 
mouse HSC-10 and HSC-1 in presence or absence of 
LPS stimulus. The assay was carried out according 
to the manufacturer’s directions. Array membranes, 
spotted in duplicate with high quality capture antibodies, 
were incubated with 2 ml of Blocking Buffer at room 
temperature for 30 min. The membranes were incubated 
with 200 μg of protein lysate from each sample (diluted 
5 fold with 1X blocking buffer) at room temperature for 
2 h. After three time washing with Wash Buffer I and 
three time washing with Wash Buffer II, a working 
solution of Biotinylated Antibody Cocktail was added to 
the membrane at 4°C overnight. Then, the membranes 
were washed as previously described and further incubated 
at room temperature for 2 h with diluted HRP-conjugated 
streptavidin solution. After washing as previously 
described, a mix of Detection Buffer C and D (1:1) was 
used as recommended by instructions provided by the 
manufacture protocol. Finally, the chemiluminescent 
signal was acquired by ChemiDoc™ MP Imaging System 
(Bio-Rad, Italy) and densitometry of the specific spots 
was performed with ImageJ v3.91 software. The results 
were expressed as relative protein expression of individual 
normalized signals of A-HSCs sample compared with that 
of NA-HSCs, treated or not with LPS.
Cell proliferation assay
LX-2 cells were seeded at a density of 6–8 × 103 
in 96-well plates and then cultured for 3 and 24 h with 
or without LPS (100 and 500 ng/ml). The DELFIA 
(Dissociation-Enhanced Lanthanide Fluorescent 
Immunoassay) Cell Proliferation Assay was performed 
following the manufacturer instructions (PerkinElmer, 
MA, USA). Specifically, after LPS stimulus LX-2 cells 
were incubated with BrdU for 3 h. The europium-labeled 
antibody was used to detect incorporated BrdU following 
Delfia Cell Proliferation Assay protocol. The dissociation 
of europium ions from the anti-BrdU antibody and the 
formation of their fluorescent chelates were obtained 
by DELFIA inducer reagent. The fluorescence, which is 
proportional to DNA synthesis, was measured by time-
resolved fluorometer 2100 Envision™ Multilabel Reader 
(PerkinElmer, MA, USA).
Biochemistry
Plasma LPS was measured using a commercial 
available Limulus amoebocyte lysate chromogenic 
endpoint assay (Hycult Biotechnology, The Netherlands) 
suitable for detection of a concentration range from 
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0.01 to 10 EU/mL. The plasma levels of IL-1β, IL-6 
and TNF-α were measured using human ELISA kit 
(BioVendor, Heidelberg, Germany).
Chromatin immunoprecipitation assay
LX-2 cells were grown to 80%-90% confluence 
in 100 mm culture plates. After treatment the culture 
medium was removed and cells were cross-linked 
with 1% formaldehyde for 15 min at room temperature 
on rotating shaker platform. The Protein-DNA cross-
linking reaction was stopped by adding glycine to a 
final concentration of 125 Mm. After 5 min of glycine 
incubation, the cells were washed twice with 1X PBS 
and collected in 1X PBS by cell scraper and subsequent 
centrifugation (3000 xg for 5 min). For each sample the 
cell pellet obtained was lysed with 1 ml of Lysis Buffer 
containing 1X protease inhibitors cocktail and sonicated 
by using a Branson Sonifier 450 (Branson, Danbury, CT, 
USA). To obtain DNA fragments of 300–1000 base pairs 
(bp) in length the following settings were used: 80% duty, 
10 cycles of 15 pulses with 2 min cooling (ice/water). 
The DNA fragment sizes were checked by loading 5 μl 
of each sonicated product on a 1% agarose gel. For each 
immunoprecipitation 500 μg of soluble chromatin was 
diluted to a final volume of 1 ml with Lysis Buffer and 
centrifuged at 20000 ´ g to remove debris. To reduce 
unspecific binding, chromatin solution was pre-cleared by 
adding 50 μl pre-blocked Protein A agarose beads. Pre-
cleared chromatin was immunoprecipitated by overnight 
incubation at +4°C with 5 μg of specific rabbit polyclonal 
anti-LITAF (sc-66945 Santa Cruz Biotech. CA, USA) and 
mouse monoclonal RNA polymerase II antibody (05–952 
Merck Millipore, Germany) as positive control, while no 
antibody was added for the background control (MOCK).
The resulting immune-complexes were captured by 
50 μl of pre-blocked Protein A agarose beads addition. 
The supernatants of each sample were saved as input (for 
positive control and data normalization). The agarose 
immunocomplexes were washed consecutively for 5 min 
on a rotisserie shaker with 1 ml of each solution: Lysis 
Buffer (50 mM Tris-HCl pH 8.0, 5 mM EDTA, 200 mM 
NaCl, 0.5% NP-40), High Salt Buffer (20 Mm Tris-HCl 
pH 8.0, 500 mM NaCl, 0.5% NP40, 0.05% SDS, 2 mM 
EDTA), Lithium Salt Buffer (10 mM Tris, pH 8.0, 250 
mM LiCl, 1% NP40, 1% Deoxycholic acid) and TE buffer 
(10 mM Tris HCl pH 8.0, 1 mM EDTA), between each 
wash the supernatant was removed by centrifugation 
for 5 min at 3000 ´ g. After the last wash, the immune-
complexes were eluted by adding 120 μl of Elution Buffer 
(20-min incubation at room temperature on a rotisserie 
shaker). DNA crosslink was reverted by heating at 65°C. 
After proteinase K digestion the immunoprecipitated 
DNA was extracted by phenol-chloroform method and 
the promoter regions of interest were amplified by PCR. 
The PCR primers (Sigma-Aldrich Inc. MO, USA) were 
designed to amplify DNA sequences encompassing LITAF 
consensus sites within IL1-β, IL-6 and TNF-α promoters 
(for primer sequences used see Fig. S5A). PCR primers 
specific for GAPDH were used for normalization (forward 
5′-GATGACATCAAGAAGGTGGTG-3′ and reverse 
5′-CATACCAGGAAATGAGCTTG-3′).
Statistics
Data were expressed as mean ± SD. Normality 
was evaluated by Shapiro-Wilk test. We planned to 
analyze differences across groups by Student’s two-tailed 
(2-group comparison) or ANOVA (≥3 group comparison), 
when variables were normally distributed, or with 
Mann-Whitney U test (2-group comparison) or Kruskal-
Wallis test (≥3 group comparison) where variables were 
non-normally distributed. Differences were considered 
statistically significant at p < 0.05.
Univariate analysis was performed by Pearson’s 
correlation coefficient, after log-transformation of 
skewed data.
For liver histology, predictors of fibrosis (presence 
vs. absence) and of inflammation (presence vs. absence) 
were assessed by multivariate logistic regression analysis. 
For logistic regression analysis, continuous variables were 
divided in quartiles (STATISTICA software, 5.1, Statsoft 
Italia, Padua, Italy).
Study approval
The study was approved by Ethical Committee of the 
Bambino Gesù Children’s Hospital and written consent was 
obtained from the parents of the children (Protocol number 
768.12). Animal experiments and cell isolation studies 
were performed according to the guidelines of the Ancona 
University Institutional Animal Care and Use Committees.
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